NVAX - NASDAQ
Novavax, Inc.
$10.57
+3.6%Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
At a Glance
Live SnapshotNovavax, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Novavax, Inc. Income Statement
NVAX • NASDAQ
| Novavax, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
1.1B | 682.2M | 556.4M | 1.6B | 197.6M | 22.4M | 18.7M | 34.3M | 31.2M | 15.4M | 36.3M | 30.7M | 20.9M | 22.1M | 14.7M | 343K | 325K | 1.1M | 1.5M | 4.7M | |
GROSS PROFIT | ||||||||||||||||||||
(71.1M) | (202.7M) | (343.8M) | (902.6M) | (0.0) | (0.0) | (113.8M) | (0.0) | (0.0) | (237.9M) | (162.6M) | (15M) | (8.2M) | (14.7M) | (7M) | (0.0) | (0.0) | (0.0) | (221K) | (6.5M) | |
1.1B | 479.4M | 212.6M | 696.3M | 197.6M | 22.4M | -95.2M | 34.3M | 31.2M | -222.6M | -126.4M | 15.7M | 12.7M | 7.4M | 7.7M | 343K | 325K | 1.1M | 1.3M | -1.8M | |
OPERATING INCOME | ||||||||||||||||||||
(489.1M) | (728.4M) | (779.1M) | (1.3B) | (1.9B) | (439.1M) | (148.3M) | (208.2M) | (202.9M) | (284.5M) | (193.5M) | (99.4M) | (65.1M) | (37M) | (29.3M) | (38.8M) | (37.7M) | (35.4M) | (31.6M) | (22.8M) | |
(150.3M) | (337.2M) | (468.9M) | (488.7M) | (298.4M) | (145.3M) | (34.4M) | (34.4M) | (34.5M) | (46.5M) | (30.8M) | (19.9M) | (14.8M) | (11M) | (11.4M) | (10.8M) | (11.9M) | (11.1M) | (14M) | (11.3M) | |
(336.8M) | (391.2M) | (737.5M) | (1.2B) | (2.5B) | (747M) | (113.8M) | (173.8M) | (168.4M) | (237.9M) | (162.6M) | (79.4M) | (50.3M) | (26.1M) | (17.9M) | (28M) | (25.8M) | (24.3M) | (17.6M) | (11.5M) | |
563.3M | -248.9M | -566.5M | -644.7M | -1.7B | -416.7M | -120.6M | -173.9M | -171.7M | -269.1M | -157.2M | -83.7M | -52.4M | -29.7M | -21.6M | -38.5M | -37.4M | -34.4M | -30.3M | -24.6M | |
PRE-TAX INCOME | ||||||||||||||||||||
(22.5M) | (20.1M) | (14.4M) | (19.9M) | (21.1M) | (15.1M) | (13.6M) | (12.2M) | (14.1M) | (13M) | (241K) | (157K) | (160K) | (32K) | (9K) | (9K) | (501K) | (1.7M) | (1.6M) | (0.0) | |
-22.5M | -20.1M | -14.4M | -19.9M | -21.1M | -15.1M | -12.1M | -13.6M | -14.1M | -13M | -241K | -157K | -160K | -32K | 127K | 180K | -501K | -724K | 1.7M | 1.5M | |
(1.9M) | (0.0) | -427.3M | -382.9M | -948.7M | -453.2M | -13K | (108K) | (67K) | -31K | -120K | (0.0) | (182K) | (45K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-121.1M | 72.3M | 23.5M | -8.9M | -28M | -1.5M | -12.1M | -10.8M | -12.1M | -10.9M | 299K | 744K | 476K | 1.2M | 2.6M | 2.3M | -991K | -1.7M | 1.7M | 1.5M | |
442.2M | -176.6M | -543M | -653.6M | -1.7B | -418.3M | -132.7M | -184.7M | -183.8M | -280M | -156.9M | -82.9M | -52M | -28.5M | -19M | -36.2M | -38.4M | -36M | -34.8M | -23.1M | |
NET INCOME | ||||||||||||||||||||
(1.9M) | (10.9M) | (2M) | (4.3M) | (29.2M) | (0.0) | (0.0) | (1.4M) | (0.0) | (2.3M) | (0.0) | (0.0) | (25K) | (77K) | (412K) | -450K | -203K | (1.7M) | -675K | (0.0) | |
440.3M | -187.5M | -545.1M | -657.9M | -1.7B | -418.3M | -130.1M | -184.7M | -183.8M | -280M | -156.9M | -82.9M | -52M | -28.5M | -19.4M | -35.7M | -38.4M | -36M | -34.8M | -23.1M |
SEC Filings
NVAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 20, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 03, 2025 | 2025 |
Related Guides
Continue your NVAX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.